Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial: Erratum
- PMID: 32168258
- PMCID: PMC7526567
- DOI: 10.1097/MPA.0000000000001517
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial: Erratum
Figures
Erratum for
-
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.Pancreas. 2020 Jan;49(1):62-75. doi: 10.1097/MPA.0000000000001455. Pancreas. 2020. PMID: 31856081 Free PMC article. Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
